Insights

Why Chemours Stock Rallied as Much as 16% in Early Trading Today

What happened
Shares of Chemours (NYSE: CC), a specialty chemical maker, rose dramatically in early trading on May 3, gaining as much as 16% in the first half hour after Wall Street opened for the day. The big story was the company’s first-quarter earnings update, which was released after the close on May 2. Investors clearly liked what they read.
So what
Chemours reported sales of $1.8 billion in the first quarter of 2022, up 23% compared to the year-ago period. Although currency fluctuations were a slight headwind, management noted volume growth of 4% and a 25% improvement in pricing as key positives in the quarter. And while the company is facing some challenges in getting the products it needs to produce the chemicals it sells, management believes it is handling the issue well. Notably, the company’s sales tally was more than 10% above analyst consensus estimates.
Image source: Getty Images.

On the bottom line, Chemours reported adjusted earnings of $1.46 per share, up a full $0.75 from the first quarter of 2021. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) improved a nearly as impressive 50%. Wall Street, meanwhile, was projecting quarterly earnings of $0.92 per share. So the company had material beats on both the top and bottom lines, which investors tend to like.
Now what
Based on the strong first-quarter results and the expectation of continued business growth, management upped the company’s adjusted EBITDA guidance for the year. Chemours’ new target is for 2022 adjusted EBITDA to fall between $1.475 billion and $1.575 billion, notably above the prior range of $1.3 billion and $1.425 billion — even more reason for the upbeat mood today.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of Chemours (NYSE: CC), a specialty chemical maker, rose dramatically in early trading on May 3, gaining as much as 16% in the first half hour after Wall Street opened for the day. The big story was the company’s first-quarter earnings update, which was released after the close on May 2. Investors clearly liked what they read.

So what

Chemours reported sales of $1.8 billion in the first quarter of 2022, up 23% compared to the year-ago period. Although currency fluctuations were a slight headwind, management noted volume growth of 4% and a 25% improvement in pricing as key positives in the quarter. And while the company is facing some challenges in getting the products it needs to produce the chemicals it sells, management believes it is handling the issue well. Notably, the company’s sales tally was more than 10% above analyst consensus estimates.

Image source: Getty Images.

On the bottom line, Chemours reported adjusted earnings of $1.46 per share, up a full $0.75 from the first quarter of 2021. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) improved a nearly as impressive 50%. Wall Street, meanwhile, was projecting quarterly earnings of $0.92 per share. So the company had material beats on both the top and bottom lines, which investors tend to like.

Now what

Based on the strong first-quarter results and the expectation of continued business growth, management upped the company’s adjusted EBITDA guidance for the year. Chemours’ new target is for 2022 adjusted EBITDA to fall between $1.475 billion and $1.575 billion, notably above the prior range of $1.3 billion and $1.425 billion — even more reason for the upbeat mood today.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!